Evercore ISI says Abbott’s (ABT) core growth drivers are still intact

Abbott Laboratories (NYSE:ABT) is included among the 12 Most Profitable Dividend Stocks to Buy in 2026. On January 23, ...

3 reasons to buy this dividend king after its steep sell-off

Investors' reaction to this Dividend King's Q4 revenue miss was overdone.

Abbott Laboratories: Buy This Dividend King On Sale Now

Abbott Laboratories fell on its latest earnings report, but I view this as a buying opportunity. Read the latest analysis on ...

Abbott Laboratories: Double-Digit Earnings Growth Makes It A Buy

Abbott's Medical Devices segment, especially CGM, continues to deliver robust double-digit growth, offsetting Nutrition ...

The Bull Case For Abbott Laboratories (ABT) Could Change Following Dividend Hike And New AFib Device Approval

In recent weeks, Abbott Laboratories raised its quarterly dividend for the 52nd consecutive year and secured CE Mark approval ...

Options Corner: Abbott Laboratories Offer Economic Insulation Ahead Of Earnings

With Abbott Laboratories set to release its earnings next week, ABT stock presents an intriguing contrarian trade following a weak spell.
Blockonomi

Abbott Laboratories (ABT) Stock Falls 8% After Missing Q4 Revenue Target

Abbott shares sank 8% as Q4 revenue of $11.5B missed the $11.8B target, with nutrition sales dropping 8.9% on price ...

The Dividend Aristocrats No One’s Talking About (And Their 30+ Year Track Records)

Dividend aristocrats get plenty of attention, but most of the time the spotlight falls on the big names like Johnson & Johnson (NYSE:JNJ), Coca-Cola (NYSE:KO), and Procter & Gamble (NYSE:PG), among ...
24/7 Wall St.

Dividend King Abbott Shows Why 52 Consecutive Increases Weren’t Luck With Strong Cash Flow Coverage

Abbott Laboratories (NYSE: ABT) doesn’t just pay dividends. It grows them. For 52 consecutive years. That’s Dividend King ...